Addition of Flucytosine to Fluconazole for the Treatment of Cryptococcal Meningitis in Africa: A Multicountry Cost-effectiveness Analysis.
BACKGROUND
Mortality from cryptococcal meningitis remains very high in Africa. In the Advancing Cryptococcal Meningitis Treatment for Africa (ACTA) trial, 2 weeks of fluconazole (FLU) plus flucytosine (5FC) was as effective and less costly than 2 weeks of amphotericin-based regimens. However, many African settings treat with FLU monotherapy, and the cost-effectiveness of adding 5FC to FLU is uncertain.


METHODS
The effectiveness and costs of FLU+5FC were taken from ACTA, which included a costing analysis at the Zambian site. The effectiveness of FLU was derived from cohorts of consecutively enrolled patients, managed in respects other than drug therapy, as were participants in ACTA. FLU costs were derived from costs of FLU+5FC in ACTA, by subtracting 5FC drug and monitoring costs. The cost-effectiveness of FLU+5FC vs FLU alone was measured as the incremental cost-effectiveness ratio (ICER). A probabilistic sensitivity analysis assessed uncertainties and a bivariate deterministic sensitivity analysis examined the impact of varying mortality and 5FC drug costs on the ICER.


RESULTS
The mean costs per patient were US $847 (95% confidence interval [CI] $776-927) for FLU+5FC, and US $628 (95% CI $557-709) for FLU. The 10-week mortality rate was 35.1% (95% CI 28.9-41.7%) with FLU+5FC and 53.8% (95% CI 43.1-64.1%) with FLU. At the current 5FC price of US $1.30 per 500 mg tablet, the ICER of 5FC+FLU versus FLU alone was US $65 (95% CI $28-208) per life-year saved. Reducing the 5FC cost to between US $0.80 and US $0.40 per 500 mg resulted in an ICER between US $44 and US $28 per life-year saved.


CONCLUSIONS
The addition of 5FC to FLU is cost-effective for cryptococcal meningitis treatment in Africa and, if made available widely, could substantially reduce mortality rates among human immunodeficiency virus-infected persons in Africa.
['Shiri|Tinevimbo|T|', 'Loyse|Angela|A|', 'Mwenge|Lawrence|L|', 'Chen|Tao|T|', 'Lakhi|Shabir|S|', 'Chanda|Duncan|D|', 'Mwaba|Peter|P|', 'Molloy|Síle F|SF|', 'Heyderman|Robert S|RS|', 'Kanyama|Cecilia|C|', 'Hosseinipour|Mina C|MC|', 'Kouanfack|Charles|C|', 'Temfack|Elvis|E|', 'Mfinanga|Sayoki|S|', 'Kivuyo|Sokoine|S|', 'Chan|Adrienne K|AK|', 'Jarvis|Joseph N|JN|', 'Lortholary|Olivier|O|', 'Jaffar|Shabbar|S|', 'Niessen|Louis W|LW|', 'Harrison|Thomas S|TS|']
D000349:Africa D000935:Antifungal Agents D003362:Cost-Benefit Analysis D015725:Fluconazole D005437:Flucytosine D006801:Humans D016919:Meningitis, Cryptococcal
flucytosine fluconazole treatment cryptococcal meningitis cost-effectiveness